Effectiveness of Inositol on clinical features, endocrine and metabolic profiles in infertile patients with polycystic ovary syndrome
PDF (English)

Ngôn ngữ sử dụng

Cách trích dẫn

Le, V. N. S., Le, M. T., Tran, T. N. Q., & Cao, N. T. (2023). Effectiveness of Inositol on clinical features, endocrine and metabolic profiles in infertile patients with polycystic ovary syndrome. Tạp Chí Phụ sản, 21(1), 73-79. https://doi.org/10.46755/vjog.2023.1.1559

Tóm tắt

Objectives: This study aimed to assess the impact of Inositol on the clinical characteristics, endocrine and metabolic profiles of infertile PCOS patients from Vietnam.

Methods: From June 2018 to June 2022, a clinical trial was undertaken at the Center for Reproductive Endocrinology and Infertility on infertile women aged 18 to 40 with PCOS. The clinical, endocrine, and metabolic features of these individuals were assessed before and after 3 months of treatment with 2g of Inositol per day. Natural pregnancy rates, adverse effects, and tolerance of Inositol have also been recorded.

Results: After three months of Inositol treatment, 18.2% of patients with oligomenorrhea experienced regular menstruation. Inositol therapy dramatically lowered hips circumference and Testosterone levels, but had no effect on other clinical characteristics, endocrine profiles, or metabolic profiles. In the overweight and obese group, weight, BMI, waist and hip circumferences decreased dramatically while regular menstrual cycles were improving in non overweight/ obse group. 9.4% of patients reported experiencing side effects; despite this, 100% of women tolerated Inositol and maintained treatment. 18.9% of them attained pregnancy, which resulted in 17% live births.

Conclusion: Inositol appears to increase menstrual cycle regularity and decrease Testosterone levels; resulting in a clinical pregnancy rate of 18.9% and a live birth rate of 17.0%. Inositol appears to be more beneficial in improving weight, BMI, waist and híp circumference in the obese and overweight population.

PDF (English)

Tài liệu tham khảo

1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertility Sterility. 2016;106(1):6-15.
2. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human reproduction. 2012;27(10):3067-73.
3. Yu H-F, Chen H-S, Rao D-P, Gong J. Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis. Medicine. 2016;95(51):1-12.
4. Lim S, Kakoly N, Tan J, Fitzgerald G, Bahri Khomami M, Joham A, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta‐analysis and meta‐regression. Obesity reviews. 2019;20(2):339-52.
5. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction update. 2010;16(4):347-63.
6. Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020;25(23):5566.
7. DiNicolantonio JJ, O'Keefe JH. Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes. Open Heart. 2022;9(1):e001989.
8. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2017;11(11):CD003053.
9. ESHRE The Rotterdam, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility Sterility. 2004;81(1):19-25.
10. Escobar-Morreale H, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human reproduction update. 2012;18(2):146-70.
11. Huang Z, Yong E-L. Ethnic differences: is there an Asian phenotype for polycystic ovarian syndrome? Best practice research Clinical obstetrics gynaecology. 2016;37:46-55.
12. Mansour A, Hashemi Taheri AP, Moradi B, Mohajeri-Tehrani MR, Qorbani M, Ghorbani Pashakolaee S, et al. Ovarian volume, not follicle count, is independently associated with androgens in patients with polycystic ovary syndrome. BMC Endocrine Disorders. 2022;22(1):1-9.
13. Yang P-K, Hsu C-Y, Chen M-J, Lai M-Y, Li Z-R, Chen C-H, et al. The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. The Journal of Clinical Endocrinology Metabolism. 2018;103(3):890-9.
14. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecological Endocrinology. 2012;28(12):969-73.
15. Zarezadeh M, Dehghani A, Faghfouri AH, Radkhah N, Naemi Kermanshahi M, Hamedi Kalajahi F, et al. Inositol supplementation and body mass index: A systematic review and meta-analysis of randomized clinical trials. Obes Sci Pract. 2022;8(3):387-97.
16. Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reproductive biomedicine online. 2008;17(4):579-82.
17. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology. 2008;24(3):139-44.
18. Papaleo E, Unfer V, Baillargeon J-P, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecological Endocrinology. 2007;23(12):700-3.
19. Gerli S, Papaleo E, Ferrari A, Di Renzo G. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347-54.
20. Le Donne M, Metro D, Alibrandi A, Papa M, Benvenga S. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019;23(5):2293-301.
21. Costantino D, Minozzi G, Minozzi E, Guaraldi. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105-10.
22. Hayamizu K, Kuramochi Y, Sumoni A, Izumo N, al e. Effects of Inositol in Women with Polycystic Ovary Syndrome: A systematic review and meta-analysis of randomized controlled trials. J Nutrition Health Food Sci 2022;10(1):1-8.
23. Tabrizi R, Ostadmohammadi V, Lankarani KB, Peymani P, Akbari M, Kolahdooz F, et al. The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Lipids in health disease. 2018;17(1):1-11.
24. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. New England Journal of Medicine. 1999;340(17):1314-20.
25. Regidor P-A, Schindler AE. Myoinositol as a safe and alternative approach in the treatment of infertile PCOS women: a German observational study. International Journal of Endocrinology. 2016;2016(49):e8842.
Creative Commons License

Công trình này được cấp phép theo Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. .


Dữ liệu downlad không hiện hữu.

Cùng tác giả